Session 1: Small Molecule Metabolites in Drug Discovery and Development
Chairs: Aaron Teitelbaum, Bingming Chen, Carley Heck, and Matthew Albertolle
Why Drug Metabolites Can be Important; Examples of Active and Toxic Metabolites
Rheem Totah, University of Washington, Seattle, Washington, USA
Modern Method of Metabolite ID: Part 1. HRMS: Instrumentation, Strategies
Mark Cancilla, Merck & Co., Inc, West Point, Pennsylvania, USA
Modern Method of Metabolite ID: Part 2. 1D and 2D NMR
Gregory Walker, Pfizer, Groton, Connecticut, USA
Predicting Metabolite Levels From in vitro Data
Ernie Callegari, Pfizer, Groton, Connecticut, USA
Accessing Metabolites of Various Types – Biosynthesis, Isolation Methods
Liz Gillam, University of Queensland
Roundtable Discussion with Speakers
Key:
Complete
Next
Failed
Available
Locked
Session 1: Small Molecule Metabolites in Drug Discovery and Development
Recorded 03/01/2023 | 60 minutes
Recorded 03/01/2023 | 60 minutes
Time Stamps:
0:00 - Welcome and Introduction
6:40 - Rheem Totah's Presentation: The Importance of Drug Metabolites: Examples of Active and Reactive Metabolites
45:37 - Mark Cancilla's Presentation: Implementation of Innovative HRMS Instrumentation Strategies to Help Accelerate Metabolite Identification and Preclinical Drug Discovery
1:34:54 - Greg Walker's Presentation: Modern Method of Metabolite ID: Part 2. 1D and 2D NMR
2:21:20 - Ernesto Callegari's Presentation: Predicting Human Metabolite Levels From in vitro Data
3:03:28 - Elizabeth Gillam's Presentation: Accessing Metabolites of Various Types – Biosynthesis, Isolation Methods
3:38:33 - Bioanalysis in ADME Science and Biotransformation, Mechanisms and Pathways Focus Group Overview
4:00:05 - Panel Discussion